Q3 2025 Zevra Therapeutics Inc Earnings Call Transcript

Nov 5, 2025 / 09:30 PM GMT

Release Date Price: $10.07 (+2.86%)

Transcript 10-Q8-K

Key Points

Positve

Zevra Therapeutics Inc (ZVRA) reported strong third-quarter net revenue of $26.1 million, driven by $22.4 million from MyFLIFA.
The company has successfully enrolled 137 patients since MyFLIFA's commercial launch, representing approximately 40% of the diagnosed NPC patient population in the U.S.
Zevra Therapeutics Inc (ZVRA) is expanding into the European market, with a marketing authorization application under review by the European Medicines Agency.
The company has a solid patent position for MyFLIFA and has requested a patent term extension in the U.S.
Zevra Therapeutics Inc (ZVRA) has increased the percentage of covered lives for MyFLIFA to 66%, indicating strong market access and reimbursement coverage.

Negative

Despite efforts, Oprova's clinical differentiation has not significantly penetrated the mature UCD market, leading to a scale-back in sales and marketing efforts.
The company reported a net loss of $500,000 for Q3 2025, although this is an improvement from the previous year's loss.
There is variability in working capital requirements due to the timing of receivables and payables, which could impact financial stability.
The Discover trial for saloprolol in vascular Ehlers-Danlos syndrome is progressing slowly, with only 44 of 150 patients enrolled.
Zevra Therapeutics Inc (ZVRA) faces challenges in converting European expanded access program patients to paid drug status, dependent on country-specific reimbursement processes.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ZVRA.OQ - Zevra Therapeutics Inc
Q3 2025 Zevra Therapeutics Inc Earnings Call
Nov 05, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you for your continued patience. Your meeting will begin shortly.

.

Good afternoon and thank you for joining Zevra's 3rd quarter 2025 Financial results and corporate update conference call. Today's call is being recorded and will be available via the investor relations section of the company's website later today.

The host for today's call is Nicole Oshur, Zev's Vice President of Investor relations and corporate communications. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you and welcome to those who are joining us

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.